Inicio / Metabolismo Óseo y Mineral (página 3)

Metabolismo Óseo y Mineral

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84

Última actualización 19/11/08Bone. 2008 Oct 17. [Epub ahead of print] Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J. Treatment with parathyroid hormone [PTH(1-84)] increases lumbar spine bone mineral density and decreases vertebral fractures, but its effects on bone microarchitecture are unknown. We obtained iliac …

Leer más »

Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial

Última actualización 19/11/08J Bone Joint Surg Am. 2008 Nov;90(11):2346-53. Miki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM. BACKGROUND: Although osteoporosis is strongly associated with hip fractures, the initiation of osteoporosis treatment following hip fractures occurs at surprisingly low rates of between 5% and 30%. Currently, most patients receiving …

Leer más »

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

Última actualización 13/10/08J Intern Med. 2008 Oct;264(4):315-32. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and …

Leer más »

Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling

Última actualización 8/07/08NULL Bone. 2008 Jun 3. [Epub ahead of print] McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Orthopaedic Research and Biotechnology, The Children’s Hospital at Westmead, Westmead Australia; Science Department, University of Technology Sydney, Australia. INTRODUCTION: It has been widely assumed that osteoclasts play …

Leer más »

Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment

Última actualización 2/05/08NULL Sebba AI. Clin Ther. 2008 Mar;30(3):443-52. Background: Oral bisphosphonates are routinely prescribed for the treatment of postmenopausal osteoporosis. In clinical trials, oral bisphosphonates have been found to increase bone mineral density (BMD) and decrease fracture risk in the majority of the treated population. However, in both clinical …

Leer más »